Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-811X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis ; volume:13 ; number:1 ; day:29 ; month:4 ; year:2015 ; pages:1-16 ; date:12.2015
Cell communication and signaling ; 13, Heft 1 (29.4.2015), 1-16, 12.2015
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12964-015-0103-0
- URN
-
urn:nbn:de:101:1-2021081920275085209746
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Philipp, Stephan
- Sosna, Justyna
- Plenge, Johannes
- Kalthoff, Holger
- Adam, Dieter
- SpringerLink (Online service)
Ähnliche Objekte (12)
Nanotoxicological profiles of clinically approved nanoplatforms
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis
TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis
Induction, execution and clinical relevance of TNF- and TRAIL-induced necroptosis
Induction, execution and clinical relevance of TNf- and TRAIL-induced necroptosis
Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs
5-iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling
Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
Electrophoretic Delivery of Clinically Approved Anesthetic Drug for Chronic Pain Therapy
Zinc oxide nanoparticles conjugated with clinically-approved medicines as potential antibacterial molecules
miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin
Nanotoxicological profiles of clinically approved nanoplatforms
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis
TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis
Induction, execution and clinical relevance of TNF- and TRAIL-induced necroptosis
Induction, execution and clinical relevance of TNf- and TRAIL-induced necroptosis
Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs
5-iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling
Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
Electrophoretic Delivery of Clinically Approved Anesthetic Drug for Chronic Pain Therapy
Zinc oxide nanoparticles conjugated with clinically-approved medicines as potential antibacterial molecules
miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin
Nanotoxicological profiles of clinically approved nanoplatforms
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis
TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis
Induction, execution and clinical relevance of TNF- and TRAIL-induced necroptosis
Induction, execution and clinical relevance of TNf- and TRAIL-induced necroptosis
Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs
5-iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling
Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
Electrophoretic Delivery of Clinically Approved Anesthetic Drug for Chronic Pain Therapy
Zinc oxide nanoparticles conjugated with clinically-approved medicines as potential antibacterial molecules